2 results
Approved WMORecruiting
Primary, improvement of the quality of life.Secondary, reduction of pain and a decrease of the number of treatments by a breast oedema therapist.
Approved WMORecruiting
Primary Objectives: - To compare the pCR rate of neoadjuvant nivolumab/BMS-986205 + GC to neoadjuvant GC alone in all randomized participants. - To compare EFS of neoadjuvant nivolumab/BMS-986205 +GC followed by continued nivolumab/BMS-986205 after…